pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Medicare delays controversial remote patient monitoring ban to 2029, opening window for provider pushback

Nov 6, 2026·read at STAT ↗RegulatoryNeutral

Medicare regulators advanced a plan to prohibit hospitals and other providers from using third‑party companies for remote patient monitoring (RPM) services, despite strong opposition from health‑tech firms, hospitals, insurers and professional groups.

The rule includes a two‑year implementation delay, pushing the effective date to 2029, which regulators say gives providers time to develop in‑house RPM capabilities. Stakeholders see the postponement as an opportunity to lobby for a revised approach.

Vendor lobbyists, such as Christopher Adamec of the Remote Monitoring Leadership Council, argue the extra time should be used to craft a better solution, while advocates continue to push back against the ban.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: After Medicare punts RPM overhaul to 2029, advocates see window to fight back”

read at STAT ↗
536 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING
topics
Psychiatry & CNS2

related stories

  • May 13BRUIN CLL-321 Trial Impact and Treatment Selectiononclive
  • May 13How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCOonclive
  • May 13Extreme heat is worsening faster for Black AmericansSTAT
  • May 13Opinion: RFK Jr.’s antidepressant deprescribing push gets one thing right — and others dangerously wrongSTAT
  • May 12Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bondonclive